Addex Therapeutics Ltd.ADXN
| Dec 31,
2019 | Dec 31,
2020 | Dec 31,
2021 | Dec 31,
2022 |
|---|
| Profit (loss) | -14,780,604 | -12,858,599 | -15,351,914 | -20,804,213 |
|---|
| Depreciation | 333,844 | 378,754 | 347,613 | 323,144 |
|---|
| Disposal of right-of-use assets | - | -4,992 | -127 | - |
|---|
| Value of share-based services | 2 | 1 | 1 | 4 |
|---|
| Post-employment benefits | 96,532 | -22,730 | -150,464 | -11,393 |
|---|
| Finance cost/(income) net | - | - | 132,050 | -215,527 |
|---|
| Decrease / (increase) in other financial assets | -5,985 | -50,962 | 47,785 | 13,980 |
|---|
| Decrease / (increase) in trade and other receivables | 154,988 | 49,655 | -96,412 | -252,090 |
|---|
| Increase in contract asset | - | - | -159,636 | -21,805 |
|---|
| Decrease/(increase) in prepayments | - | - | -616,992 | 844,980 |
|---|
| (Decrease)/increase in payables and accruals | 2 | -1,585,550 | 883,837 | -427,388 |
|---|
| Decrease in contract liability | - | - | -733,668 | - |
|---|
| Decrease in deferred income | - | - | -86,481 | - |
|---|
| Services paid in shares | 289,214 | 285,745 | 164,980 | - |
|---|
| Net cash used in operating activities | -9,482,104 | -12,180,067 | -14,705,185 | -16,437,185 |
|---|
| Purchase of property, plant and equipment | 28,459 | 59,414 | 31,549 | 581 |
|---|
| Proceeds from decrease in non-current financial assets | - | - | 1,236 | 3,553 |
|---|
| Net cash from/(used in) investing activities | -43,254 | -59,414 | -30,313 | 2,972 |
|---|
| Proceeds from issuing shares | - | - | 10 | - |
|---|
| Costs / deferred costs paid on issue of shares | - | 272,005 | 2 | - |
|---|
| Proceeds from sale of treasury shares-shelf registration | - | - | - | 1 |
|---|
| Costs paid on sale of treasury shares-shelf registration | - | - | - | 304,009 |
|---|
| Proceeds from sale of pre-funded warrants | - | - | 5 | 3 |
|---|
| Costs paid on sale of pre-funded warrants | - | - | 569,228 | 576,117 |
|---|
| Proceeds from exercise of warrants | - | - | - | 25,241 |
|---|
| Sale of treasury shares under liquidity and sale agency agreement | - | - | - | 450,973 |
|---|
| Costs paid on sale of treasury shares under sale agency agreement | - | - | - | 3,487 |
|---|
| Cost paid on issue of treasury shares | - | - | - | 248,354 |
|---|
| Principal element of lease payment | 316,793 | 367,412 | 309,617 | 288,076 |
|---|
| Interest received | 36,874 | 35,305 | 5,322 | 29,251 |
|---|
| Interest paid | 128,518 | 69,502 | 63,012 | 48,897 |
|---|
| Net cash from financing activities | -463,695 | 46,399 | 16 | 3 |
|---|
| Increase/(decrease) in cash and cash equivalents | -9,989,053 | -12,193,082 | 2 | -13,331,525 |
|---|
| Exchange difference on cash and cash equivalents | -144,302 | -648,681 | 122,470 | -196,225 |
|---|